**Core Concept**
Osteosclerotic bone metastasis refers to the process by which cancer cells from a primary tumor invade and replace normal bone tissue, leading to increased bone density and sclerosis. This phenomenon is a result of the interaction between cancer cells and the bone microenvironment, involving the activation of various signaling pathways and the release of growth factors.

**Why the Correct Answer is Right**
Osteosclerotic bone metastasis is most commonly associated with prostate cancer. This is due to the presence of prostate-specific antigen (PSA) in prostate cancer cells, which stimulates the production of parathyroid hormone-related protein (PTHrP) in osteoblasts. PTHrP, in turn, promotes the activation of osteoclasts, leading to increased bone resorption and osteosclerosis. The interaction between prostate cancer cells and the bone microenvironment creates a vicious cycle that contributes to the development of osteosclerotic bone metastasis.

**Why Each Wrong Option is Incorrect**
* **Option A:** Breast cancer is more commonly associated with osteolytic bone metastasis, characterized by bone destruction and loss of bone density. While breast cancer can also lead to osteosclerotic metastasis, this is less common compared to prostate cancer.
* **Option B:** Lung cancer can also metastasize to bone, but it is more commonly associated with osteolytic lesions. The bone metastasis pattern in lung cancer is often related to the tumor's histological subtype and the presence of specific genetic mutations.
* **Option D:** Renal cell carcinoma (RCC) is a type of kidney cancer that can metastasize to bone, but it is not typically associated with osteosclerotic bone metastasis. RCC bone metastases are often osteolytic and can be accompanied by the development of brown tumors.

**Clinical Pearl / High-Yield Fact**
Prostate cancer is the most common malignancy to metastasize to bone, and osteosclerotic bone metastasis is a hallmark of this disease. This phenomenon is closely related to the production of PSA and PTHrP, which can be used as biomarkers for the diagnosis and monitoring of prostate cancer.

**Correct Answer:** C. Prostate cancer.